CONSUMER HEALTHCARE PRODUCTS ASSOCIATION for CONSUMER HEALTHCARE PRODUCTS ASSOCIATION
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Manufacturing MAN
Microbeads - H.R. 1321/S. 1424 - Microbead-Free Waters Act of 2015. Would prohibit the distribution of cosmetic products containing synthetic plastic microbeads after January 1, 2018; all sections. OTC Drug Review Monograph - legislation to update and modernize the Over-the-Counter Drug Review Monograph system, which regulates the manufacture, labeling, and marketing of specific over-the-counter (OTC) drugs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN GAY | — |
| TRAVIS GIBBONS | — |
| LINDSAY A MORRIS | — |
Alcohol and Drug Abuse ALC
Dextromethorphan H.R. 3250/Senate companion, the "DXM Abuse Prevention Act" (DAP) - legislation that would ban the sale of over-the-counter cough and cold medications containing the active ingredient dextromethorphan (DXM) to minors under the age of 18. Additionally, would ban the sale of bulk, unfinished DXM to entities not registered with the U.S. Food and Drug Administration; all sections).
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN GAY | — |
| TRAVIS GIBBONS | — |
| LINDSAY A MORRIS | — |
Taxation/Internal Revenue Code TAX
Flexible spending arrangements (FSA) and health savings accounts (HSA) - H.R. 1270/S. 709 - Restoring Access to Medication Act. Repeals prohibition in Patient Protection and Affordable Care Act (P.L. 111-148, P.L. 111-152) against use of flexible spending arrangement (FSA) and health savings account (HSA) funds on over-the-counter medications; all sections.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN GAY | — |
| TRAVIS GIBBONS | — |
| LINDSAY A MORRIS | — |
Chemicals/Chemical Industry CHM
Toxic Substances Control Act of 1976 (P.L. 94-469) H.R. 2576 - TSCA Modernization Act. Modernize and update the Toxic Substances Control Act of 1976 (TSCA; P.L. 94-469) by allowing the Environmental Protection Agency (EPA) to prioritize consideration of chemicals based on risk and set minimum federal standards for chemical regulation; all sections. S. 697 - Frank R. Lautenberg Chemical Safety for the 21st Century Act. Modernize and update the Toxic Substances Control Act of 1976 (TSCA; P.L. 94-469) by allowing the Environmental Protection Agency (EPA) to prioritize consideration of chemicals based on risk and set minimum federal standards for chemical regulation; all sections.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN GAY | — |
| TRAVIS GIBBONS | — |
| LINDSAY A MORRIS | — |
Food Industry (safety, labeling, etc.) FOO
Dietary Supplements Food and Drug Administration (FDA) draft "Guidance for Industry: New Dietary Ingredient Notifications and Related Issues." Possible reintroduction of "Free Speech About Science Act of 2011" (H.R. 1364, 112th Congress) - would establish conditions under which a food or dietary supplement label may characterize the relationship of a nutrient in the food or supplement to a disease or health-related claim; all sections.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN GAY | — |
| TRAVIS GIBBONS | — |
| LINDSAY A MORRIS | — |
Pharmacy PHA
Pseudoephedrine Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient, common in popular cold and allergy medications (no bill number) and oppose prescription requirement (no bill number). Oral Contraceptives S. 1438 - Allowing Greater Access to Safe and Effective Contraception Act. Grants priority review of applications to switch oral contraceptive drugs from prescription to nonprescription (over-the-counter) status; all sections S. 1532 - Affordability is Access Act. Clarifies that all oral contraceptive products be covered by insurance and provided to consumers without cost, regardless of prescription/nonprescription (over-the-counter) status; all sections. Over-the-counter (OTC) medicines; Manufacturing and importation of OTC drugs; Mandatory recall authority of the FDA; Rx-to-OTC Switch Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN GAY | — |
| TRAVIS GIBBONS | — |
| LINDSAY A MORRIS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.